BioInvent International AB (publ) (FRA:BIX0)

Market Cap	184.89M +5.1%
Revenue (ttm)	22.15M +533.7%
Net Income	-29.30M
EPS	-0.45
Shares Out	n/a
PE Ratio	n/a
Forward PE	11.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	743
Open	2.930
Previous Close	2.860
Day's Range	2.930 - 2.995
52-Week Range	2.045 - 3.680
Beta	n/a
RSI	53.88
Earnings Date	Feb 26, 2026

About FRA:BIX0

BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company’s drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and a type of blood cancer; BI-1206, an anti-FcyRIIB antibody in Phase 1/2a trial for the treatment of non-Hodgkin’s lymphoma, as well as Phase 1/2a trial to treat advanced solid tumors; BI-19...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1996
• Employees: 124
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: BIX0

Financial Performance

In 2024, FRA:BIX0's revenue was 44.69 million, a decrease of -37.47% compared to the previous year's 71.46 million. Losses were -429.38 million, 30.0% more than in 2023.

Financial numbers in SEK